What's the deal with peptides? The hyped market under U.S. review
The substances under review -- including BPC-157, TB-500 and Semax -- are among those Joe Biden's administration restricted from compounding, notably over lack of human clinical trial data
· 7/23/2026, 7:57:35 AM· 2 min read
The substances under review -- including BPC-157, TB-500 and Semax -- are among those Joe Biden's administration restricted from compounding, notably over lack of human clinical trial data
Read original story →Related stories
health
Beyond childhood: the expanding possibilities of cochlear implants for hearing restoration
health
Self-medication may be temptingly easy. But it can have serious consequences
health
ICMR-NIN consortium calls for healthier school food environment, stricter regulations on marketing
health